MedDataX Logo

Key Aspects of Medical Practice in Patients With Haemophilia A

NCT ID: NCT02996942

Last Updated: 2018-12-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Study Classification

OBSERVATIONAL

Study Start Date

2012-07-31

Study Completion Date

2017-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The KAPPa project has the aim to create an international database in which information about clinical features, therapeutic management, burden of illness and costs of severe and moderate haemophilia A patients from different countries and sites is collected. The aim of this project is to analyse the influence of such different characteristics on medical, psychosocial and economic outcomes in patients over the long-term.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Long-term Anticoagulation in a Patient With Severe Hemophilia A

NCT07314983

Hemophilia A
RECRUITING

Clot Formation and Clot Stability in Patients With Severe Haemophilia A

NCT00279578

Hemophilia A
COMPLETED NA

A Comparison Study of Bypassing Agent Therapy With and Without Tranexamic Acid in Haemophilia A Patients With Inhibitor

NCT01800435

Hereditary Factor VIII Deficiency Disease With Inhibitor
COMPLETED PHASE4

Global Haemostatic Methods Following Administration of Bypassing Agents to Patients With Haemophilia With Inhibitors

NCT02453542

Hemophilia
RECRUITING

rFVIIa Prophylaxis in Children With Hemophilia A and Inhibitors

NCT01105546

Hemophilia A With Inhibitors
UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

1000 patients with hemophilia A will be enrolled using a webbased registry. Key quality factors that will be registered are : hemophilia joint Health score (HJHS), annual bleed rate, quality of Life (EQ5D), as well as dosing of replacement therapy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Joint Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Replacement therapy

Hemophilia A receiving replacement therapy (prophylaxis or on demand)

Factor VIII replacement

Intervention Type BIOLOGICAL

Patients receive their usual treatment

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Factor VIII replacement

Patients receive their usual treatment

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

factor VIII

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* severe haemophilia A (factor VIII\<1%)
* moderate (factor VIII\<5%)
* signed informed consent
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Lund University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2012/118

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Individually Tailored Prophylaxis in Patients With Severe Hemophilia A
NCT00995046 TERMINATED NA
Platelet Function in Patients With Hemophilia A
NCT02093065 COMPLETED
German Pediatric Hemophilia Research Database
NCT02912143 RECRUITING
Evaluation of the Reasons and Consequences of Bleeding in Late Teens and Early Adulthood Patients With Severe Hemophilia A
NCT00782470 COMPLETED
Efficacy and Cost Effectiveness of Pharmacokinetic Dosing in Haemophilia A
NCT02697370 COMPLETED PHASE4
Acquired Hemophilia A and Autoimmunity. Study of Lymphocyte Populations and Myeloid-Derived Suppressor Cells
NCT04805021 RECRUITING
Tissue Factor Pathway Inhibitor (TFPI) and Haemorrhagic Manifestations in Haemophilia A and B Patients
NCT02540187 COMPLETED
Global Hemostatic Methods in Hemophilia and Von Willebrand's Disease
NCT02061033 UNKNOWN
Turkish Acquired Haemophilia Registry
NCT01403740 UNKNOWN
Study Evaluating Inhibitor Specificity in Hemophilia A
NCT00151385 WITHDRAWN PHASE4
EVALUATION of the OVERALL HAEMOSTATIC CAPACITY of MIM8 with GLOBAL HAEMOSTASIS ASSAYS and FIBRIN CLOT ULTRASTRUCTURE
NCT06212505 COMPLETED
Patient Functioning and Well-being, Economic, and Clinical Impact of Hemophilia A and Its Treatment
NCT02396862 COMPLETED
Patterns of Hemophilia Care in Assiut Children Patients
NCT05980377 UNKNOWN
Trial of Rituximab Versus Oral Cyclophosphamide to Eradicate or Suppress Autoimmune Anti-Factor VIII Antibodies in Acquired Hemophilia A
NCT00306670 TERMINATED PHASE2/PHASE3
A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A
NCT01580293 COMPLETED PHASE2/PHASE3
Joint Status in Subjects With Severe Hemophilia A in Relation to Different Treatment Regimens
NCT00927667 COMPLETED PHASE4
Use of a TGA and TEM in the Assessment of the Efficacy of Treatment With APCC or rFVIIa
NCT01856751 UNKNOWN
Efficacy and Safety of ADVATE Standard Prophylaxis to Hemophilia A
NCT02280265 UNKNOWN NA
A Study of Factor Inhibitors in Adult Patients With Hemophilia and Von Willebrand's Disease in Upper Egypt
NCT04106323 UNKNOWN
Hemophilia Adult Prophylaxis Study: Factor VIII in Severe Hemophilia A
NCT01405742 TERMINATED PHASE3
Comparison of Efficacy, Safety and Costs of Recombinant FVIII Products Between On-demand and Secondary Prophylaxis Groups in Haemophilia A Patients
NCT01817868 COMPLETED
Treatment of Hemophilia A Patients With FVIII Inhibitors
NCT04023019 RECRUITING
Hemophilia Inhibitor Previously Untreated Patient Study
NCT01652027 COMPLETED
A Non-interventional Retrospective Study of the Current Treatment Practice in European Haemophilia Care
NCT02049099 COMPLETED
Phenotypic Heterogeneity in Hemophilia A: An Investigation of the Role of Platelet Function
NCT02225483 COMPLETED